Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing
Conclusion: Overall, 53%, 62% and 14% of carbapenemase-producing E. coli, K. pneumoniae and A. baumannii harbours only AMEs, indicating the role of plazomicin use. Plazomicin can be used both for ESBLs as “carbapenem-sparing agent” and carbapenemase producers as “colistin-sparing agent.” For optimal use, it is essential to know the molecular epidemiology of resistance in a given geographical region where plazomicin empirical therapy is considered.
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Agila Kumari Pragasam S Lydia Jennifer Dhanalakshmi Solaimalai Dhiviya Prabaa Muthuirulandi Sethuvel Tanya Rachel Divyaa Elangovan Karthick Vasudevan Karthick Gunasekaran Balaji Veeraraghavan Source Type: research
More News: Acinetobacter | Antimicrobial Resistance | Epidemiology | Gastroenteritis | Genetics | India Health | Microbiology | Study | Urinary Tract Infections